Recursion Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended June 30, 2026, submitted on August 5, 2026.

Key Highlights

  • Share count: As of July 31, 2026, there were 535,342,170 shares of Class A common stock outstanding.
  • Exchange listing: Class A Common Stock (par value $0.00001) is listed on the Nasdaq Global Select Market under the symbol RXRX.
  • Filer status: Recursion is classified as a large accelerated filer and is not a smaller reporting company or emerging growth company.
  • Reporting period: The quarterly report covers the period ended June 30, 2026.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Recursion Pharmaceuticals Q2 2026 Quarterly Disclosure Details

Recursion Pharmaceuticals, Inc. (Nasdaq Global Select Market: RXRX), a Delaware corporation headquartered at 41 S Rio Grande Street, Salt Lake City, UT 84101, filed its Form 10-Q for the quarterly period ended June 30, 2026. According to the filing, as of July 31, 2026, the company had 535,342,170 shares of Class A common stock outstanding, each with a par value of $0.00001.

The filing confirms that the registrant has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically pursuant to Rule 405 of Regulation S-T. The company is classified as a large accelerated filer and indicated it is not a shell company.

The quarterly report contains forward-looking statements, which the filing notes are subject to the company's cautionary language. These statements address, among other things, research and development programs, clinical study timing and progress, collaboration milestones, AI-enabled technology development, regulatory filings, and cash management. The filing explicitly states that all such statements other than statements of historical facts are forward-looking statements, and identifies them by terms including "may," "will," "should," "expect," and similar expressions.

What Was Disclosed

Recursion Pharmaceuticals submitted its Form 10-Q for the period ended June 30, 2026, confirming 535,342,170 Class A shares outstanding as of July 31, 2026, its large accelerated filer classification, and its continued listing on the Nasdaq Global Select Market under RXRX.